Ixazomib Citrate (MLN9708) Analogue

製品コードS2181 バッチS218101

化学情報

	Synonyms	N/A	Storage (From the date of receipt)	3 years -20°C powder 1 years -80°C in solvent
	化学式	C₂₀H₂₃BCl₂N₂O₉
	分子量	517.12	CAS No.	1201902-80-8
Solubility (25°C)*	体外	DMSO	103 mg/mL (199.18 mM)
		Water	Insoluble
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

製品説明

Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

プロトコル(参考用のみ)

参考

[4] Ruzena Vlasakova, et al. WO2016165677A1.

+ 展开

カスタマーフィードバック

: Data from [Data independently produced by , , Mol Cell Proteomics, 2012, 11(12): 1898-912]

: Data from [Data independently produced by , , PLoS One, 2016, 11(8):e0161068]

: Data from [Data independently produced by , , Int J Parasitol Drugs Drug Resist, 2018, 8(3):394-402]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns [ EMBO J, 2023, 42(17):e111719]	PubMed: 37431963
A Drosophila model of diabetic neuropathy reveals a role of proteasome activity in the glia [ iScience, 2023, 26(6):106997]	PubMed: 37378316
TRPA1 promotes melanosome phagocytosis in keratinocytes via PAR-2/CYLD axis [ J Dermatol Sci, 2022, S0923-1811(22)00125-6]	PubMed: 35637111
HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs [ PLoS One, 2022, 17(12:e0274704)]	PubMed: 36480501
LAMP3 inhibits autophagy and contributes to cell death by lysosomal membrane permeabilization [ Autophagy, 2021, 1-19]	PubMed: 34802379
Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer [ Cell Chem Biol, 2021, S2451-9456(21)00400-1]	PubMed: 34525344

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。